Every material Form 8-K Coda Octopus Group, Inc. filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Interim Chief Financial Officer Gayle Jardine will retire effective August 3, 2026. On July 1, 2026, Coda Octopus finalized Mark Kelly as its Chief Financial Officer, effective the same date, which gives shareholders a named successor for the finance role.
Gayle Jardine, interim CFO, retires effective August 3, 2026.
Mark Kelly's appointment was finalized July 1, 2026, effective August 3, 2026, subject to a three-month probationary period that the company may extend by two months.
Kelly will receive an annual base salary of £165,000 (about $218,625 at an exchange rate of $1.325), plus discretionary bonuses and a restricted stock grant valued at $40,000 that vests in two equal annual installments starting October 31,
Kelly was Finance Director at Medac Pharma from 2024 to 2025 and held finance roles at Chubb Insurance, Twist Bioscience and Charles River Laboratories from 2016 to 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Coda Octopus Group, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →